KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) and SCYNEXIS (NASDAQ:SCYX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.
Valuation & Earnings
This table compares KalVista Pharmaceuticals and SCYNEXIS”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| KalVista Pharmaceuticals | N/A | N/A | -$183.44 million | ($3.95) | -3.77 |
| SCYNEXIS | $3.75 million | 8.39 | -$21.29 million | ($0.51) | -1.47 |
Insider & Institutional Ownership
54.4% of SCYNEXIS shares are held by institutional investors. 4.3% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 4.9% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares KalVista Pharmaceuticals and SCYNEXIS’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| KalVista Pharmaceuticals | N/A | -214.88% | -81.87% |
| SCYNEXIS | -862.89% | -60.54% | -41.77% |
Analyst Ratings
This is a summary of current ratings and target prices for KalVista Pharmaceuticals and SCYNEXIS, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| KalVista Pharmaceuticals | 1 | 0 | 8 | 0 | 2.78 |
| SCYNEXIS | 1 | 0 | 1 | 0 | 2.00 |
KalVista Pharmaceuticals presently has a consensus target price of $29.17, suggesting a potential upside of 95.62%. SCYNEXIS has a consensus target price of $3.00, suggesting a potential upside of 300.00%. Given SCYNEXIS’s higher probable upside, analysts plainly believe SCYNEXIS is more favorable than KalVista Pharmaceuticals.
Volatility and Risk
KalVista Pharmaceuticals has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500.
Summary
SCYNEXIS beats KalVista Pharmaceuticals on 10 of the 13 factors compared between the two stocks.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
About SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
